CNBC’s Jim Cramer on Friday pointed out the number of biopharma mergers and acquisitions that have closed or been announced over the
Tag: ImmunoGen Inc
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some
No More Posts Available.
No more pages to load.